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Background: Radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC) is widely utilized as a
bridge to liver transplant with limited evidence to support efficacy. The purpose of the present study was
to measure the effect of RFA on time to drop-off in HCC-listed patients.
Methods: Patients with Milan criteria tumours listed between January 1999 and June 2007 were
stratified into RFA (n = 77) and No Treatment groups (n = 93).
Results: The primary effectiveness of RFA was 83% (complete radiographic response). RFA was
associated with a longer median wait time to transplant (9.5 vs. 5 months). Tumour-specific drop-off
events were equivalent between RFA (21%) and No Treatment (12%) groups (P = 0.11). Controlling for
wait time, there was no difference in overall (P = 0.56) or tumour-specific drop-off (P = 0.94). Furthermore,
there were no differences in 5-year overall or tumour-free survivals from list date or transplant. Using
multivariate analysis, the likelihood of receiving a transplant and patient survivals were associated with
tumour characteristics (AFP, tumour number and size) and not with bridge therapy or waiting time.
Discussion: RFA allows patients to be maintained longer on the waiting list without negative conse-
quences on drop-off or survival compared with no treatment. Post-transplant outcomes are affected more
by tumour characteristics than RFA or wait time.
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Introduction
Liver transplantation is the most effective treatment for patients
with hepatocellular carcinoma (HCC) arising in the setting of
cirrhosis.1 Liver transplant for HCC is only effective if the major-
ity of patients awaiting transplantation survive and remain eli-
gible to receive this treatment.2–4 The primary goal of bridging
therapy is to prevent waiting list drop-off by reducing tumour
progression while secondary goals include the prevention of HCC
recurrence and improving survival after liver transplantation.5–9
In 2006, more than 50% of all patients listed for liver transplant
in the United States with a diagnosis of HCC received bridging
therapy.6 Although widely offered and applied, recent reviews have
uniformly concluded that there is no evidence in the literature
proving the efficacy of bridging therapies in maintaining patients
on the list or improving post transplant survival.5,8–12
Tumour ablation is a process whereby known or suspected
HCC tumour nodules are destroyed by thermal or chemical injury
via either a percutaneous or a surgical approach. Tumour destruc-
tion is then monitored by radiological measures. There are a
variety of ablation techniques although radiofrequency ablation
(RFA) has become the most common technique used in North
America.6 RFA has been shown to be safe; with minimal mor-
bidity and mortality both in transplant and non-transplant*Contributed equally to first authorship.
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populations.13–16 There are several single centre reports of using
RFA as a bridge to transplant, documenting the safety of this
intervention.17–20 Although conceptually attractive, there are no
controlled studies to suggest that RFA truly impacts relevant
HCC transplant patient outcomes.
The present study was undertaken to determine the efficacy of
RFA as a bridge to transplant in patients with Milan criteria HCC.
The primary aim was to determine whether RFA increased the
time taken to drop-off the waiting list. The secondary aims were to
determine whether RFA improved the chances of being trans-
planted, overall and disease-free survival (DFS). We hypothesized
that RFA as a bridge to transplant would decrease waiting list
drop-off in a time to event model.
Methods
Ethics approval for this study was obtained from the Research
Ethics Board of University Health Network (Protocol no.
06-0181-CE).
Patients
During the period between January 1999 and June 2007, all
patients with the diagnosis of HCC who were placed on the liver
transplant waiting list or listed patients who developed an HCC
while waiting for liver transplant were evaluated for this study.
Only patients whose HCC tumour pattern fulfilled the Milan
criteria were included in this study. These patients were identified
using the Organ Transplant Tracking Registry (OTTR, HKS
Medical Information Systems, Omaha, NE), which is an internal
web-based electronic medical record that encompasses all patients
evaluated for a solid organ transplant at the University Health
Network, University of Toronto. For the purpose of the present
study, the diagnosis of HCC was verified by review of the pre-
transplant radiological imaging, pre-transplant tumour histology
(when performed) and the liver explant pathology.
A total of 343 patients were listed and/or transplanted with a
diagnosis of HCC. The following patients were excluded from this
study: 105 patients with a tumour pattern that exceeded the Milan
criteria, 24 patients with incidental tumours identified by explant
pathology that were not suspected or recognized before trans-
plant, 4 patients who received their RFA procedures at a different
institution and 3 patients who received a liver transplant at a
different institution. An additional 18 patients with a history of
a partial hepatectomy for HCC were excluded as these patients
already had ‘recurrent HCC’ and likely exhibited more aggressive
tumour biology. To specifically analyse the effect of RFA as bridg-
ing therapy vs. no treatment, Milan criteria patients who received
bridging therapies other than RFA were also excluded: 14 patients
that received a percutaneous ethanol injection (PEI), 3 patients
who received transarterial chemoembolization (TACE) therapy
and 2 patients who received external beam radiotherapy.
There were a total of 170 patients with the diagnosis of HCC
recognized prior to transplant with a tumour pattern that radio-
graphically fulfilled the Milan criteria: 77 patients received RFA
as a sole bridging therapy and 93 patients received no bridging
therapy.
Bridging therapy
RFA interventions were offered to patients at the University of
Toronto beginning in 1999 and became our institution’s recom-
mended treatment (over TACE or PEI) for patients with small
(4 cm), few (3 lesions) unresectable HCCs that were remote
from major biliary structures. Given the equipoise between RFA
and TACE as effective bridge therapy, RFA evolved as our institu-
tional standard for reasons of local expertise, resource availability
and overall lower morbidity in favour of RFA. Bridging therapies
were offered to patients after review at a multidisciplinary HCC
Tumour Review Board. RFA as bridging therapy was recom-
mended to patients with ablatable lesions who were expected to
have a transplant wait time more than 3 months. Wait time was
estimated based upon the patient’s position on the transplant
waiting list and availability of living liver donor. Specifically, if on
the waiting list at the time of listing, the waiting time (current date
minus list date) of the top tumour patient with the same ABO
blood type was 3 months, or if the patent had a potential live
donor volunteer to be assessed, then the patient was counselled by
a Transplant Surgeon regarding the relative risks and benefits
of bridge therapy, and ‘no bridging therapy’ was recommended.
Through surveillance with CT scans every 3 months, a Transplant
Surgeon reassessed RFA bridging recommendations if the live
donor did not materialize, or if the waiting time was estimated to
be an additional 2–3 months, the patient was counselled again,
and bridge therapy was recommended. The use of RFA as a bridg-
ing therapy over time has increased in frequency in parallel with
the increased numbers of patients being listed for transplant and
the prolongation of waiting times.
Radiofrequency ablation therapy was delivered via a percuta-
neous approach in 97% of patients by one of three Interventional
Radiologists. RFA was provided to the remaining patients via
open operations (3%) jointly by the interventional radiologist
and transplant surgeon. Percutaneous RFA procedures were
performed on an outpatient basis with conscious sedation using
titrated doses of intravenous midazolam and fentanyl, and utiliz-
ing ultrasound and/or CT guidance. A multi-tined LeVeen elec-
trode (Boston Scientific Corporation, Natick, MA, USA) was used
for most (79%) ablations. Technical details of the ablative thera-
pies were prospectively entered into an Interventional Radiology
database along with pre-intervention imaging characteristics and
post-treatment radiological response.
Pre-transplant clinical care
Patients on the liver transplant waiting list with HCC were given a
priority listing of 1T. The Canadian Liver Transplant allocation
agreement assigns the following Medical Status to patients on the
waiting list: (i) patients at home, (ii) patients hospitalized for a
liver failure-related diagnosis, (iii) patients hospitalized with a
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creatinine >200 mm/l or grade 3 encephalopathy, or (iv) patients
intubated in the intensive care unit. Organs are allocated accord-
ing to the patient priority listing on a national and provincial
level; the priority 1T lies between priorities 1 and 2.21 As all
tumour patients are eligible for a priority of at least 1T, waiting
time is the dominant factor in the likelihood of being offered
an organ.
Patients were monitored by a transplant surgeon while on
the liver transplant waiting list. Computed tomography (CT)
or magnetic resonance imaging (MRI) was performed every 3
months. Indications for de-listing (i.e. drop-off or transplanta-
tion) were identified for all patients. Drop-off events were further
classified into medical (cardiovascular, sepsis, upper gastrointes-
tinal bleed and medically unfit) and tumour specific (lymph node
metastases, peritoneal disease, tumour progression, pulmonary
metastases, tumour rupture and vascular invasion).
Study design
This cohort study was a retrospective analysis. Patients were cat-
egorized into Radiofrequency Ablation or No Treatment groups.
Primary outcomes were time to event analysis (listing to drop-
off). Analyses were performed for both drop-off as a result of all
causes (HCC-specific and medical aetiologies) as well as tumour-
specific drop-off. Wait time was calculated from the date of listing
until either transplant or delisting. For patients who developed
HCC while on the list, wait time was adjusted to begin at the date
of the diagnosis of HCC. Patients were censored at the time of
transplant or at the time they refused transplant. Survival analysis
was based upon the intention to treat.
Statistical analysis
Characteristics of the patients in each group were compared using
t-tests and Mann–Whitney U-tests for continuous outcomes and
c2-tests of association for categorical outcomes. Survival analysis
was performed by the University of Toronto Statistical Consulting
Service using SAS statistical software (version 9.1, SAS Institute,
Cary, NC, USA). The objective of the present study was to assess
how various predictors could affect the risk of a patient dropping
off the list while waiting for a transplant. As the probability of such
an event (dropping off the list) must increase the longer a patient
is on the list, we used survival analysis models which allowed us to
test various predictors while controlling for differences between
subjects due to differences in time on the list. Patient characteris-
tics that we screened were: age at the time of listing, gender, blood
type (O or not), RFA treatment (yes or no), model for end-stage
liver disease (MELD) score at the time of listing, AFP at the time
of listing and aetiology. For categorical candidate predictor vari-
ables, we constructed Kaplan–Meier survival curves of time to
drop-off for each level of the predictor (SAS: Proc Lifetest) and
used a log-rank test to test for differences in the survival function
between the levels. We used Cox Regression (SAS : Proc Phreg) to
assess the relationship between continuous predictors such as
age and the survival function. The following predictors were not
significant and were not used in subsequent models: aetiology
(P = 0.37), MELD at list (P = 0.47) and gender (P = 0.59). Age was
not significant (P = 0.29) but was retained in models because of its
potential clinical importance. All other predictors were significant
and were retained in the final models. We used Cox proportional
hazard and logistic regression models to conduct a multivariate
analysis of the candidate predictors, which allowed us to test for
the significance of individual predictors while controlling for all
other predictors in the model. Interactions were removed from
the models if they were not significant and only final models
are reported.
After initial analysis of the whole cohort, further subgroup
analysis was undertaken with 1:1 nearest neighbour propensity
score matching. Waiting time, age, tumour number, tumour size,
AFP and MELD score were incorporated into this analysis to
ensure the relationship between predictor variables and outcome
variables remained consistent across the RFA vs. no treatment
group.
Results
Patients and demographics
Between January 1999 and June 2007, 170 patients who were listed
for liver transplant with a diagnosis of HCC that fulfilled the
Milan criteria by radiographic assessment either at the time of
listing or while active on the waiting list were eligible for the
primary analysis of this study. There were 77 patients that received
RFA as a sole bridging therapy and 93 patients that received no
bridging therapy (Table 1). No patients were lost to follow-up. All
patients have either received a liver transplant or have experienced
a drop-off event.
The only statistically significant difference in demographics
(Table 1) between the groups was that fewer patients with a diag-
nosis of alcoholic liver disease received RFA as a bridge to trans-
plant (12% RFA vs. 26% No Treatment, P = 0.02). Investigations
could not identify any explanation for this observation. The mean
listing medical MELD score at the time of listing was 14 in the RFA
group compared with 15 in the No Treatment group (Tables 1,
P = 0.33). There was no difference in the type of transplant (live
vs. deceased donor) between the RFA and No Treatment group.
The median waiting time to transplantation was significantly
greater in the RFA group compared with the No Treatment group
(9.5 months vs. 5.0 months, P < 0.001). The differences in time on
the list were most pronounced in the quartile of patients with the
shortest waiting time (only 13% of the RFA group was trans-
planted within 2.5 months of listing compared with 32% in the
No Treatment group) and the longest waiting time quartile (35%
of the RFA group waited longer than 12.8 months compared with
only 18% of the No Treatment group).
Tumour characteristics
The median alpha-fetoprotein levels at time of listing and the
other tumour characteristics (including size and number) were
similar between the RFA and No Treatment groups (Table 1).
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Details of the RFA procedures
Details of the RFA procedures are listed in Table 2. The procedures
were performed by interventional radiologists on an outpatient
basis using conscious sedation and percutaneous electrode inser-
tion in 97% of the patients. The ablation electrodes were inserted
into the HCC tumours using ultrasound (US) (47%), CT (10%)
or a combination of US and CT localization (43%). The mean
number of separate RFA procedures was 1.4 per patient (range
1–4). The mean number of tumours treated per RFA procedure
was 1.1 and the mean largest tumour diameter was 2.6 cm. The
primary technique effectiveness was 83% (64/77) as measured
by a complete radiological (ablative) response on the first post-
procedure contrast-enhanced imaging study.
There were two minor complications of the RFA interventions
including asymptomatic left portal vein thrombosis and a vaso-
vagal reaction that occurred immediately after RFA application.
Liver transplants have been performed in both of these patients
with minor complications. There was one delayed tumour rupture
three and a half months after ablation that was not attributed as
a direct complication of the ablation. This patient did not receive
a liver transplant.
Patient drop-off from the waiting list analysis
At the time of analysis, all patients in both groups had received a
transplant, refused transplantation and were delisted, or dropped
Table 1 Patient demographics at the time of listing
RFA No
treatment
Significance
Total patients 77 93
Age mean (range) 5635–76 5528–71 0.68
Gender 0.25
Male 66 (86%) 75 (81%)
Female 11 (14%) 18 (19%)
Blood group 0.26
O 37 (48%) 41 (44%)
A 31 (40%) 33 (35%)
B 9 (12%) 15 (16%)
AB 0 (0%) 4 (4%)
Aetiologya
Hepatitis B 17 (22%) 18 (19%) 0.66
Hepatitis C 49 (64%) 52 (56%) 0.31
Alcohol 9 (12%) 24 (26%) 0.02
NASH/ cryptogenic 3 (4%) 4 (4%) 0.89
Other 1 (1%) 5 (5%) 0.15
Tumour characteristics
Mean number 1.33 1.35
Mean maximal size 2.5 cm 2.4 cm
Median AFP (Range) 280,000–65 200,000–119 0.60
AFP > 200 16 (21%) 21 (23%) 0.78
Mean MELD score
(range)b
147–26 156–25 0.33
Time on list (months) <0.001
<2.5 10 (13%) 30 (32%)
2.6–5.0 18 (23%) 25 (27%)
5.1–12.7 22 (29%) 21 (23%)
>12.8 27 (35%) 17 (18%)
Time on list median
(range)
9.5 (0.8–51.1) 5.0 (0.1–30.3)
aSome patients had more than one aetiology of liver disease.
bMELD scores reported are the medical MELD, without any exception
points.
MELD, model for end-stage liver disease; NASH, non-alcoholic
steato-hepatitis.
Table 2 Technical details and complications of the RFA procedures
Ablation access Percutaneous 75 (97%)
Open surgical 2 (3%)
Imaging guidance US 36 (47%)
CT 8 (10%)
CT & US 33 (43%)
Total RFA procedures 1 RFA 58 (75%)
2 RFA 12 (16%)
3 RFA 5 (6%)
4 RFA 2 (3%)
Mean/ patient 1.4 (range 1–4)
Number of tumours
ablateda
1 tumour 70 (91%)
2 tumours 6 (8%)
3 tumors 0 (0%)
4 tumors 1 (1%)
Mean number ablated 1.1 (range 1–4)
Diameter of largest
tumour nodulea
2.6 cm (range 0.6–4.5 cm)
Ablation electrodes
utilized
LeVeen 61 (79%)
Cool-tip 7 (9%)
Berchtold 7 (9%)
RITA StarBurst 2 (3%)
Primary technique
effectivenessab
83% (64/77)
Complications Major none
Minor n = 2 Left portal vein
thrombus
Vasovagal
reaction
No deaths
aData presented for the first RFA procedure only.
bDefined as patients with a complete radiological response as measured
on the first contrast enhanced imaging post-ablation.
LeVeen electrode (Boston Scientific, Natick, MA); Cool-tip electrode
(Covidien/Valleylab, Boulder, CO); Berchtold electrode (Integra Life-
Sciences, Plainsboro, NJ); RITA StarBurst electrode (AngioDynamics,
Queensbury, NY).
RFA, radiofrequency ablation; US, ultrasound; CT, computed tomogra-
phy; cm, centimetres.
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off the waiting list for medical or tumour-specific reasons
(Table 3).
More patients in the RFA group requested delisting from the
waiting list (9% RFA vs. 1% No Treatment, P = 0.01). Notably, six
out of the seven requested delisting in the RFA group because they
had a sustained radiographical response. Of these six patients,
four remain free of disease, one patient developed an additional
HCC that was completely ablated and one patient developed
a peri-ablation recurrence that was resected. There were similar
percentages of patients who dropped-off for medical reasons (4%
RFA vs. 7% No Treatment, P = 0.65). For tumour-specific reasons,
there was a trend towards a higher drop-off in the RFA group
(21% RFA vs. 12% No Treatment, P = 0.11). The major differences
in tumour events for the RFA group were the development of
pulmonary metastases in five, peritoneal disease in one and
tumour rupture in one, compared with the No-treatment group
who dropped-off for local progression in two and lymph node
metastases in one. The development of vascular invasion was
equivalent between groups (12% RFA vs. 9% No Treatment,
P = 0.43).
Although there were numerically more drop-offs events in the
RFA group, the corresponding waiting time was also longer in the
RFA group, which would increase the probability of experiencing
a drop-off event. Waiting time was controlled for using survival
analysis modelling. There was no significant difference in the time
to drop-off between the RFA and No Treatment groups for all
causes (medical + tumour; Fig. 1a) or for tumour-specific aetiol-
ogy (Fig. 1b). The overall drop-off rate during the first 12 months
after listing was approximately 2% per month for each group, and
the rate of delisting for tumour specific drop-off events was
approximately 1.7% per month.
Transplantation
Transplantation was achieved in 75% of those patients treated
with RFA as a bridge and 83% of those without treatment
(P = 0.141). Tumour characteristics were most strongly associated
with a reduction in the odds of achieving a transplant (Table 4).
Patients with an AFP > 200 (OR 0.205, P < 0.001), greater number
of tumours (OR 0.532, P = 0.037), bilobar disease (OR 0.344,
Table 3 Aetiology of patient drop-off from the liver transplant waiting
list
RFA No
treatment
Significance
Total patients 77 93
Aetiology of drop-off
Refused transplant* 7 (9%) 1 (1%) 0.01
Medical (total) 3 (4%) 5 (7%) 0.65
Cardiovascular 0 1
UGIB 1 0
Unfit 2 4
Tumor specific (total) 16 (21%) 11 (12%) 0.11
LN metastases 0 1
Peritoneal disease 1 0
Progression 0 2
Pulmonary metastases 5 0
Rupture 1 0
Vascular invasion 9 8
Transplant 0.8
Deceased donor organ 45 (58%) 65 (69%)
Live donor right lobe 6 (8%) 11 (12%)
Transplant + Refused
transplant
58 (75%) 77 (83%) 0.31
*6/7 RFA patients who refused a transplant were interpreted to have a
complete radiological response to tumour ablation.
UGIB, upper gastro-intestinal bleed; LN, lymph node; HCC, hepatocel-
lular carcinoma; MELD, model for end-stage liver disease.
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Figure 1 (a) Overall drop-off from the waiting list. (b) Tumour-specific
drop-off from the waiting list
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P = 0.025), larger tumours (OR 0.665, P = 0.040) and a higher
stage at listing (OR 0.155, P = 0.013) had a lower chance of being
transplanted. This association was maintained on multivariate
analysis for AFP > 200 (P < 0.001), higher tumour number
(P = 0.013) and larger tumours (P = 0.014). The patients receiving
RFA did not have a lower odds of undergoing transplant despite
a lower overall percentage of patients transplanted.
After propensity matching of covariates the effect of RFA on
drop-off and achieveing transplantation was reanalysed. Good
matching of covariates was achieved, with no statistically signifi-
cant differences for the included covariates. With matching there
was no difference in the treatment effect of RFA on drop-off
(t-statistic -2.26, P = 0.79) or achieving transplant (t-statistic
-2.41, P = 0.79).
Non-transplanted patients (waiting list
drop-off events)
The 1-, 3- and 5-year survival for those patients who were delisted
was 87%, 76% and 55% for RFA group, which was significantly
higher than the No treatment group where the survival was 71%,
39%, 30% (P = 0.009). On univariate analysis, the risk of death
was lower in females (HR 0.307, P = 0.041), and those receiving
RFA (HR 0.299, P = 0.014). On Multivariate analysis only RFA was
associated with a lower risk of dying. Tumour characteristics did
not influence risk of death in those patients delisted.
Explant pathology
Details of the explant pathology are listed in Table 4. There
were no statistically significant differences in explant pathology
between those patients who received RFA vs. No Treatment.
Survivals
There was no difference in the overall median follow-up time
between the RFA and No Treatment groups (41 vs. 46 months,
P = 0.44). After transplantation there was also no difference
observed in the median follow-up time between the RFA and No
Treatment groups (30 vs. 41 months, P = 0.075). There was no
significant difference in the overall survival (OS) (P = 0.75) or
DFS (P = 0.24) as calculated from the time of listing (intent to
treat analysis) between the RFA and No Treatment groups.
(Fig. 2a–b) After liver transplant, there were nine deaths (four
HCC/ five non-HCC related) and one HCC recurrence out of 51
RFA patients transplanted (20% event rate). In comparison, there
were 19 deaths (8 HCC/ 11 non-HCC) and 2 HCC recurrences in
the 76 No Treatment group patients transplanted (25% event
rate). The corresponding post-liver transplant OS (P = 0.76) and
DFS (P = 0.86) curves did not demonstrate a statistical difference.
(Fig. 3a–b).
Table 4 Explant tumour characteristics
RFA No
treatment
Significance
Total patients 77 93
Milan stage
Within Milan 44 (76%) 61 (80%) 0.54
Outside Milan 14 (24%) 15 (20%)
Microvascular invasion 11 (22%) 15 (19.7%) 0.76
Macrovascular invasion 2 (4%) 4 (5%) 0.75
Number of tumours
(median)
2 1.5 0.80
Size of largest tumour
(median)
2.5 2.7 0.90
Bilobar disease 18 (36%) 22 (29%) 0.405
Pathological grade
Well differentiated 1 (2%) 8 (12%) 0.11
Moderately differentiated 39 (89%) 48 (74%)
Poorly differentiated 9 (4%) 14 (8%)
P = 0.75
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Figure 2 (a) Overall survival in all hepatocellular carcinoma (HCC)
patients. Time is calculated from the date of listing. (b) Tumour-free
survival in all HCC patients. Time is calculated from the date of
listing
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Details of the predictors of survival are listed in Table 5. Based
upon the intention to treat on both univariate and multivariate
analysis, survival was lower in those patients with an AFP > 200
(P = 0.01) and a higher stage at listing (P = 0.008). Other tumour
characteristics and treatment with RFA were not significantly
associated with OS.
Discussion
The benefits of locoregional treatment for HCC patients prior
to liver transplantation are unclear.5,8–12 In a situation where the
waiting time for liver transplantation is long, there is a perception
by both the physicians and patients that not treating patients with
HCC is unacceptable, despite the absence of evidence supporting
short- or long-term benefit. The present study has demonstrated
that RFA can be safely performed for patients with tumours
within the Milan Criteria. RFA also appeared to allow patients
to be maintained for a longer period of time on the transplant
waiting list without any adverse effect on drop off, achieving
transplant or post-transplant survival, a significant benefit when
waiting times are prolonged.
RFA was safely performed percutaneously 97% of the time,
with a high primary technique effectiveness of 83% and a very
low complication rate. Six of the 77 patients treated with RFA
(intended as a bridge to transplant) had a sustained radiographi-
cal response such that these patients elected not to proceed with
liver transplant. In the group of patients who were delisted, the
survival in the RFA group was superior compared with the No
treatment group (55% vs. 30%), and was equivalent to other
treatments with curative intent such as surgery.22–24 RFA thus
became an effective destination therapy for a small portion of
patients and avoided the need for liver transplant – a clinically
significant advantage to the use of RFA. In the setting of a long
waiting time for transplant, the durability of the RFA response
can be assessed and the need for transplantation for HCC be
reconsidered.
There was no significant difference in tumour-specific drop-off,
although the incidence of drop-off events tended to be higher in
the RFA group. RFA was not observed to halt the development of
vascular invasion while on the transplant waiting list (12% RFA
vs. 9% No Treatment, P = NS). Moreover, the overall and tumour-
free drop-off rates were equivalent when controlling for the longer
waiting time in the RFA group. As the majority of the patients
were transplanted within 12 months, there were too few patients
remaining in the survival analysis after 12 months to determine
the efficacy of RFA bridging therapy for those patients with a
longer waiting time to transplantation, where the benefits of
treatment may be most pronounced. Previous studies18,25 have
suggested that RFA can reduce drop off on the waiting list com-
pared with historical controls, however, these patients had longer
waiting times than that those in our study and the cohorts used
for comparison were not matched.
Perhaps the most clinically important impact of RFA for HCC
patients that are typically transplanted within 1 year of listing is
the ability of RFA to maintain patient eligibility on the transplant
list. This is important because, while a clinician may estimate a
short waiting time, this study demonstrates that the waiting time
may be unpredictably prolonged, as 41% of the no-RFA group
waited more than 5 months. The median time on the waiting list
was significantly longer in the RFA group (9.5 vs. 5 months) and
despite this, the rate of transplantation and drop offs in the
RFA group were equivalent to those with much shorter waiting
list times. Furthermore, the explant pathology was equivalent
between these two groups suggesting that RFA may halt the pro-
gression of tumour growth. The importance of RFA being able to
keep patients’ tumour burden within the Milan criteria without
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Figure 3 (a) Overall survival in hepatocellular carcinoma (HCC)
patients that received a liver transplant. Time is calculated from the
date of transplantation. (b) Tumour-free survival in HCC patients that
received a liver transplant. Time is calculated from the date of
transplantation
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increasing the rate of drop off or being detrimental to survival
has implications for the priority given to these patients on the
transplant waiting list.
Although the time-to-drop-off was similar between the RFA
and No Treatment groups, there were some differences. The RFA
group experienced a greater incidence of drop-off for tumour
events, notably pulmonary metastases (n = 5), peritoneal
metastases (n = 1) and tumour rupture (n = 1). These unexpected
events may be a reflection of the tumour biology but given that
none of these were seen in the No Treatment group, they may
also have occurred as a consequence of treatment. Peritoneal
metastases and tumour rupture are a known, albeit very rare,
direct complication of the ablation technique. Although the lung
is a common destination for HCC metastases in advanced disease,
pulmonary metastases should be a relatively uncommon event in
patients with a HCC tumour pattern that fulfils the Milan criteria.
During the ablation process, it is common to see micro-air
bubbles escaping the ablation zone via the hepatic veins to the
systemic circulation. If these contents contain viable tumour
emboli, the lung would be the first microcirculation filter. This
proposed mechanism, however, is purely speculative. The overall
procedure-related local complication rates were similar to those
published in the literature.
In the present study, tumour characteristics were the best pre-
dictors of a failure to achieve transplantation and are probably
reflective of the tumour biological behaviour. The main determi-
nant of survival for non-resectable HCC within the Milan criteria
is whether or not the patient is transplanted. Patients treated
with RFA achieved the same overall and tumour-free survival,
despite significantly longer waiting times. Given the excellent
post-transplant survival for HCC this finding is not unexpected,
and is consistent with several recently published studies that post-
transplant survival is equivalent for patients treated with RFA.5,8–12
It is also notable that the 1997–2006 UNOS liver transplant review
has suggested that patients who received bridging therapy on
the waiting list had a slightly higher survival at 3 years (76% vs.
71%, P = 0.03).6 There are also single centre reports suggesting
that multimodal bridging therapies may increase post-transplant
survival.26–28 TACE is the predominant bridging therapy in
the United States (60–70%)6 and thus it is possible that TACE
provides an additional survival benefit above that of RFA.
This study has limitations inherent to all retrospective analy-
ses. Probably the most important one is whether or not this is an
appropriate comparison between RFA and No Treatment groups
– specifically whether the groups were at the same risk of drop-
off or survival? For uniformity and generalizability, only patients
with a HCC that fulfilled the Milan criteria were considered and
the demographics and tumour characteristics were similar. To
reduce confounding variables, patients treated with other bridg-
ing therapies (TACE, ethanol ablation, radiation) or previous
hepatectomy were excluded. The major systemic bias in this
study is the criteria used to select patients for RFA: their tumours
must have been safely ‘ablatable’ and their wait time was pre-
dicted to exceed 3 months based upon their position on the
blood-type specific waiting list and availability of a living liver
donor. Thus, the RFA patients may have been at a higher risk for
drop-off as they were predictably on the wait list longer. The
waitlist drop-off analysis, however, accounts for the difference in
waiting times and demonstrated that the time to drop-off was
similar between the groups for both tumour-specific and overall
(medical and tumor-specific) indications. Furthermore, the
nearest neighbour propensity score matching analysis demon-
strated equivalent results between the RFA and No Treatment
groups. On the other hand, many in the No-treatment group
may have been at higher risk for drop-off or recurrence if their
tumours were ‘not-ablatable’ for high-risk factors such as size,
very exophytic nature or proximity to major biliary and vascular
structures that might indicate having a worse or risky ‘biology’.
These differences could only be normalized with a randomized
prospective clinical trial.
The present study analyses the largest reported single centre
cohort of patients treated with RFA as a bridge to liver transplant
Table 5 Logistic regression model for factors predicting achieving transplantation
Variable Odds 95% confidence Significance
Ratio Interval Univariate Multivariate
Gender 1.05 0.40–2.83 0.92 ns
Age 0.97 0.92–1.02 0.20 ns
AFP > 200 0.21 0.09–0.47 <0.001 <0.001
Waiting time 1.02 0.98–1.05 0.38 ns
RFA 0.68 0.32–1.45 0.32 ns
Tumour numbera 0.53 0.29–0.96 0.04 0.01
Bilobar diseasea 0.34 0.14–0.87 0.03 ns
Size of largest tumoura 0.67 0.45–0.98 0.04 0.01
UNOS stagea 0.16 0.04–0.68 0.01 ns
aData from time of listing.
AFP, alpha fetoprotein; RFA, radiofrequency ablation.
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compared with a No-Treatment group treated during the same
period. This study should be generalizable as it mirrors current
clinical practice in many transplant centres with similar waiting
times. Although no significant advantage of RFA in waitlist drop-
off or HCC recurrence was identified, the RFA patients may have
been at higher risk for these events because of the centre’s criteria
for selecting HCC patients for RFA bridging and despite this, the
patients were maintained for longer on the waiting list without
any negative consequences with respect to drop-off or survival.
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